BRPI0920351A2 - composição farmacêutica para prevenção e tratamento de diabetes ou obesidade compreendendo um composto que inibe a atividade de dipeptidil peptidade-iv, e outros agentes antidiabéticos ou antiobesidade como ingredientes ativos - Google Patents
composição farmacêutica para prevenção e tratamento de diabetes ou obesidade compreendendo um composto que inibe a atividade de dipeptidil peptidade-iv, e outros agentes antidiabéticos ou antiobesidade como ingredientes ativosInfo
- Publication number
- BRPI0920351A2 BRPI0920351A2 BRPI0920351A BRPI0920351A BRPI0920351A2 BR PI0920351 A2 BRPI0920351 A2 BR PI0920351A2 BR PI0920351 A BRPI0920351 A BR PI0920351A BR PI0920351 A BRPI0920351 A BR PI0920351A BR PI0920351 A2 BRPI0920351 A2 BR PI0920351A2
- Authority
- BR
- Brazil
- Prior art keywords
- obesity
- antidiabetic
- diabetes
- prevention
- compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/02—Halogenated hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2008-0101932 | 2008-10-17 | ||
| KR1020080101932A KR101054911B1 (ko) | 2008-10-17 | 2008-10-17 | 디펩티딜펩티다아제-ⅳ의 활성을 저해하는 화합물 및 다른 항당뇨 또는 항비만 약물을 유효성분으로 함유하는 당뇨 또는 비만의 예방 및 치료용 약학적 조성물 |
| PCT/KR2009/005970 WO2010044637A2 (ko) | 2008-10-17 | 2009-10-16 | 디펩티딜펩티다아제-ⅳ의 활성을 저해하는 화합물 및 다른 항당뇨 또는 항비만 약물을 유효성분으로 함유하는 당뇨 또는 비만의 예방 및 치료용 약학적 조성물 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| BRPI0920351A2 true BRPI0920351A2 (pt) | 2016-03-08 |
| BRPI0920351A8 BRPI0920351A8 (pt) | 2016-10-04 |
| BRPI0920351B1 BRPI0920351B1 (pt) | 2020-09-29 |
| BRPI0920351B8 BRPI0920351B8 (pt) | 2021-05-25 |
Family
ID=42107077
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0920351A BRPI0920351B8 (pt) | 2008-10-17 | 2009-10-16 | composição farmacêutica para prevenção e tratamento de diabetes ou obesidade |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US8440669B2 (pt) |
| EP (1) | EP2351567B1 (pt) |
| JP (1) | JP5364168B2 (pt) |
| KR (1) | KR101054911B1 (pt) |
| CN (1) | CN102256605B (pt) |
| AU (1) | AU2009304028B2 (pt) |
| BR (1) | BRPI0920351B8 (pt) |
| CA (1) | CA2740570C (pt) |
| ES (1) | ES2656812T3 (pt) |
| HK (1) | HK1160031A1 (pt) |
| HU (1) | HUE036475T2 (pt) |
| IL (1) | IL212330A (pt) |
| MX (1) | MX2011004064A (pt) |
| NZ (1) | NZ592567A (pt) |
| PT (1) | PT2351567T (pt) |
| RU (1) | RU2466727C1 (pt) |
| TR (1) | TR201802120T4 (pt) |
| WO (1) | WO2010044637A2 (pt) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103848825B (zh) * | 2012-12-03 | 2017-01-25 | 中国药科大学 | 具有α‑葡萄糖苷酶抑制活性的锍糖类天然产物及其衍生物的制备方法及用途 |
| EP3015106B1 (en) * | 2013-06-26 | 2021-08-11 | Dong-A ST Co., Ltd. | Composition for preventing or treating renal diseases, comprising a dpp-iv inhibitor |
| CN103599540B (zh) * | 2013-11-15 | 2016-09-14 | 深圳奥萨医药有限公司 | 含有格列奈类药物和b族维生素的药物组合物及其用途 |
| CN115109161B (zh) * | 2022-06-28 | 2023-08-11 | 广东赛尔生物科技有限公司 | 含有间充质干细胞的减肥药物组合物 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19823831A1 (de) | 1998-05-28 | 1999-12-02 | Probiodrug Ges Fuer Arzneim | Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen |
| GB0014969D0 (en) * | 2000-06-19 | 2000-08-09 | Smithkline Beecham Plc | Novel method of treatment |
| UA74912C2 (en) * | 2001-07-06 | 2006-02-15 | Merck & Co Inc | Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes |
| US7262207B2 (en) * | 2002-09-19 | 2007-08-28 | Abbott Laboratories | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) |
| AU2003298596B2 (en) * | 2002-10-18 | 2008-12-18 | Merck Sharp & Dohme Corp. | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| ES2311117T3 (es) | 2002-12-10 | 2009-02-01 | Novartis Ag | Combinacion de un inhibidor de dpp-iv y un compuesto ppar-alfa. |
| US7205409B2 (en) * | 2003-09-04 | 2007-04-17 | Abbott Laboratories | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) |
| ES2585353T3 (es) | 2004-05-12 | 2016-10-05 | Synchronoss Technologies, Inc. | Sistema de identificación de contactos avanzado |
| DOP2006000008A (es) | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1 |
| CA2606188A1 (en) | 2005-05-02 | 2006-11-09 | Merck & Co., Inc. | Combination of dipeptidyl peptidase-iv inhibitor and a cannabinoid cb1 receptor antagonist for the treatment of diabetes and obesity |
| GT200600218A (es) | 2005-06-10 | 2007-03-28 | Formulación y proceso de compresión directa | |
| JP2007024960A (ja) | 2005-07-12 | 2007-02-01 | Internatl Business Mach Corp <Ibm> | システム、プログラムおよび制御方法 |
| JOP20180109A1 (ar) | 2005-09-29 | 2019-01-30 | Novartis Ag | تركيبة جديدة |
| JP5165582B2 (ja) * | 2005-12-16 | 2013-03-21 | メルク・シャープ・エンド・ドーム・コーポレイション | ジペプチジルペプチダーゼ−４インヒビターとメトホルミンとを組み合わせた医薬組成物 |
| MEP7609A (en) | 2005-12-28 | 2011-12-20 | Therapeutic agent for diabetes | |
| JP2008031064A (ja) * | 2006-07-27 | 2008-02-14 | Astellas Pharma Inc | ジアシルピペラジン誘導体 |
| KR101007497B1 (ko) * | 2007-04-19 | 2011-01-12 | 동아제약주식회사 | 베타 아미노기를 포함하는 ｄｄｐ－ⅳ 저해제, 이의제조방법 및 이를 유효성분으로 함유하는 당뇨 또는 비만예방 및 치료용 약학적 조성물 |
-
2008
- 2008-10-17 KR KR1020080101932A patent/KR101054911B1/ko active Protection Beyond IP Right Term
-
2009
- 2009-10-16 PT PT98207871T patent/PT2351567T/pt unknown
- 2009-10-16 ES ES09820787.1T patent/ES2656812T3/es active Active
- 2009-10-16 EP EP09820787.1A patent/EP2351567B1/en active Active
- 2009-10-16 CN CN200980151387.8A patent/CN102256605B/zh active Active
- 2009-10-16 NZ NZ592567A patent/NZ592567A/xx unknown
- 2009-10-16 HU HUE09820787A patent/HUE036475T2/hu unknown
- 2009-10-16 WO PCT/KR2009/005970 patent/WO2010044637A2/ko active Application Filing
- 2009-10-16 RU RU2011119616/15A patent/RU2466727C1/ru active
- 2009-10-16 AU AU2009304028A patent/AU2009304028B2/en active Active
- 2009-10-16 BR BRPI0920351A patent/BRPI0920351B8/pt active IP Right Grant
- 2009-10-16 US US13/124,150 patent/US8440669B2/en active Active
- 2009-10-16 TR TR2018/02120T patent/TR201802120T4/en unknown
- 2009-10-16 CA CA2740570A patent/CA2740570C/en active Active
- 2009-10-16 JP JP2011532021A patent/JP5364168B2/ja active Active
- 2009-10-16 MX MX2011004064A patent/MX2011004064A/es active IP Right Grant
-
2011
- 2011-04-14 IL IL212330A patent/IL212330A/en active IP Right Grant
-
2012
- 2012-01-20 HK HK12100710.5A patent/HK1160031A1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL212330A0 (en) | 2011-06-30 |
| WO2010044637A3 (ko) | 2010-08-19 |
| KR101054911B1 (ko) | 2011-08-05 |
| CA2740570A1 (en) | 2010-04-22 |
| EP2351567A4 (en) | 2013-12-04 |
| RU2466727C1 (ru) | 2012-11-20 |
| BRPI0920351A8 (pt) | 2016-10-04 |
| ES2656812T3 (es) | 2018-02-28 |
| US20110201624A1 (en) | 2011-08-18 |
| BRPI0920351B8 (pt) | 2021-05-25 |
| NZ592567A (en) | 2012-08-31 |
| JP5364168B2 (ja) | 2013-12-11 |
| WO2010044637A9 (ko) | 2010-10-07 |
| CN102256605B (zh) | 2014-05-07 |
| HUE036475T2 (hu) | 2018-07-30 |
| KR20100042786A (ko) | 2010-04-27 |
| AU2009304028B2 (en) | 2013-05-16 |
| US8440669B2 (en) | 2013-05-14 |
| AU2009304028A1 (en) | 2010-04-22 |
| PT2351567T (pt) | 2018-02-12 |
| JP2012505876A (ja) | 2012-03-08 |
| EP2351567B1 (en) | 2017-11-22 |
| EP2351567A2 (en) | 2011-08-03 |
| TR201802120T4 (en) | 2018-03-21 |
| WO2010044637A2 (ko) | 2010-04-22 |
| HK1160031A1 (en) | 2012-08-10 |
| IL212330A (en) | 2015-11-30 |
| CN102256605A (zh) | 2011-11-23 |
| CA2740570C (en) | 2015-02-03 |
| BRPI0920351B1 (pt) | 2020-09-29 |
| MX2011004064A (es) | 2011-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2008000691A1 (es) | Compuestos derivados de dihidro y tetrahidro oxazolopirimidinonas sustituidas; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de la esquizofrenia, epilepsia, entre otras enfermedades. | |
| CL2009000173A1 (es) | Compuestos derivados de urea-tetrahidroxiquinoxalina; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; y uso para el tratamiento y la prevencion de la obesidad y la diabetes, resistencia a la insulina, sindrome metabolico, entre otros. | |
| BRPI0921063B8 (pt) | composto, e, composição agonística para receptor de melanocortina | |
| IL225198A (en) | Aminotetrahydropyrenic Compounds, Pharmaceutical Preparations Containing Them and Their Use in the Treatment of Diabetes | |
| CL2007002348A1 (es) | Compuestos heterociclicos, moduladores de la actividad de la estearoil-coa-desaturasa; composicion farmaceutica, util para el tratamiento de enfermedades tales como diabetes, dislipidemias, obesidad, anorexia y acne. | |
| CL2013001104A1 (es) | Composicion farmaceutica que comprende un inhibidor de sglt2 y una insulina; y uso para tratar una enfermedad o afeccion tal como diabetes mellitus, diabetes mellitus tipo 1 y 2, entre otras. | |
| CL2007003495A1 (es) | Compuestos derivados de heterociclos condensados sustituidos, inhibidores de la actividad de la akt; composicion farmaceutica; y uso para el tratamiento o prevencion del cancer. | |
| CL2013001964A1 (es) | Compuestos derivados de heterociclos, como inhibidores de bace 1 o 2; composicion farmaceutica que los comprende; combinacion farmaceutica; y su uso para el tratamiento o prevencion de la enfermedad de alzheimer o deterioro cognitivo leve, resistencia a la insulina, diabetes tipo 2, entre otras. | |
| WO2007002597A3 (en) | Modified-release formulations of a bupropion salt | |
| CL2008000593A1 (es) | Uso de compuestos derivados de heterociclos sustituidos; composicion farmaceutica que comprende a dichos compuestos y otros agentes activos; y su uso para tratar diabetes, enfermedad aterosclerotica de las arterias entre otras enfermedades. | |
| CL2007002610A1 (es) | Compuestos derivados de bipiridina sustituida; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento y/o la profilaxis de enfermedades tales como hipertonia, diabetes, infarto de miocardio, entre otras. | |
| CL2007002197A1 (es) | Compuestos derivados de indol; procedimiento de preparacion; compuesto intermediario; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de diabetes mellitus, retinopatia diabetica, hiperglucemia, hiperl | |
| CL2007003803A1 (es) | Compuestos derivados de sulfonamidas; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer, dislipidemia, diabetes, obesidad, infeccion. | |
| CL2007001886A1 (es) | Compuestos derivados de ureas de piperidina o pirrolidina; procedimiento de preparación; composición farmacéutica; y su uso como moduladores de la actividad de la 11ß-hidroxiesteroide deshidrogenasa tipo 1 (11ßhsd1) para tratar la obesidad, diabetes, resistenacia a la insulina, síndrome de cushing e hipertensión, entre otros. | |
| CL2008000594A1 (es) | Uso de compuestos derivados de heterociclos; composicion farmaceutica que comprende a dichos compuestos y otros agentes activos; y su uso para tratar diabetes, enfermedad arterial coronaria entre otras enfermedades. | |
| MX2009002903A (es) | Combinacion de un ligando del receptor nmda y un compuesto con afinidad por el receptor 5-ht6. | |
| WO2011090270A3 (ko) | 오스모틴을 포함하는 신경질환의 예방 및 치료용 조성물 | |
| BRPI0907977A2 (pt) | Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças | |
| MX2012006734A (es) | Tiazolidinadionas moderadoras de receptores activados por proliferador de peroxisoma (ppar) y combinaciones para el tratamiento de obesidad y otras enfermedades metabolicas. | |
| MX2010005385A (es) | Medicamentos topicos para la terapia antimicotica. | |
| WO2008070268A3 (en) | Pharmaceutical compositions | |
| BRPI0815591A2 (pt) | Composto, composição farmacêutica, uso de um composto, e, método para tratar uma doença, condição ou distúrbio. | |
| BRPI0907974A2 (pt) | Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças | |
| EP2438923A4 (en) | COMPOSITION FOR THE PREVENTION OR TREATMENT OF OBESITY-RELATED DISORDERS MEDIATED BY AMPK ACTIVATION AND THE ACTIVE INGREDIENTS OF WHICH HAVE 2,5-BIS-ARYL-3,4-DIMETHYLTETRAHYDROFURAN LIGNANS | |
| BRPI0924669A2 (pt) | composto, uso de um composto, método para tratar a diabete melito e/ou obesidade, e, composição farmacêutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25D | Requested change of name of applicant approved |
Owner name: DONG-A SOCIO HOLDINGS CO., LTD. (KR) |
|
| B25A | Requested transfer of rights approved |
Owner name: DONG-A ST CO., LTD. (KR) |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 29/09/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/10/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |